Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
353 articles about Travere Therapeutics
-
Shares of Retrophin have plunged more than 24% in premarket trading after the San Diego-based company announced its Phase III treatment for pantothenate kinase-associated neurodegeneration did not stack up against placebo.
-
Retrophin Reports Second Quarter 2019 Financial Results
8/6/2019
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
-
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
7/31/2019
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET.
-
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
7/28/2019
Retrophin, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney stones.
-
Retrophin to Report Second Quarter 2019 Financial Results
7/23/2019
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
-
Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria.
-
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
-
Two weeks after filing a lawsuit against his former company from prison, Martin Shkreli has reached a settlement with Retrophin.
-
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
6/18/2019
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
-
Retrophin to Present at Upcoming June 2019 Investor Conferences
5/30/2019
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
-
Retrophin Appoints Sandra E. Poole to Board of Directors
5/13/2019
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin
-
Retrophin Reports First Quarter 2019 Financial Results
5/7/2019
Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.
-
Retrophin to Report First Quarter 2019 Financial Results
4/23/2019
Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
-
Retrophin to Present at Upcoming March 2019 Investor Conferences
3/5/2019
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March
-
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
2/28/2019
Retrophin, Inc. joins the National Organization for Rare Disorders, the European Organisation for Rare Diseases, and others worldwide to recognize Rare Disease Day® 2019.
-
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
2/26/2019
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
-
Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2/14/2019
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York Cityon Thursday, February 28, 2019 at 3:30 p.m. ET.
-
Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
2/12/2019
Retrophin, Inc. announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets.
-
Retrophin Provides Corporate Update and 2019 Outlook
1/7/2019
Top-line readout of pivotal FORT Study in PKAN expected 3Q19
-
Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer
1/3/2019
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success